Realm Therapeutics plc American Depositary Shares
RLM
RLM was delisted on the 30th of July, 2019.
0 hedge funds and large institutions have $0 invested in Realm Therapeutics plc American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% less funds holding
Funds holding: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $5.88M → $0 (-$5.88M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.87M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.57M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$351K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$46K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$43K |
RLM Hedge Fund Activity: Q3 2019 in Review
0 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Realm Therapeutics plc American Depositary Shares (RLM) for Q3 2019, worth a combined $0 — down 100% from $5.88M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RLM and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was OrbiMed, exiting entirely with an estimated $2.87M sold.
- 0 institutional investors held Realm Therapeutics plc American Depositary Shares (RLM) as of Q3 2019, down from 7 in Q2 2019.
- Funds reported $0 of Realm Therapeutics plc American Depositary Shares stock for Q3 2019, down 100% quarter-over-quarter.
- 0 funds opened new Realm Therapeutics plc American Depositary Shares positions in Q3 2019 and 7 closed out, a net change of -7 holders.
- The largest Realm Therapeutics plc American Depositary Shares seller in Q3 2019 was OrbiMed, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2019.